HCWB

HCW Biologics Inc.

1.28 USD
+0.18 (+16.36%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

HCW Biologics Inc. stock is down -16.34% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 May’s closed higher than April.

About HCW Biologics Inc.

HCW Biologics Inc. focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. Its lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis. HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia.